Zostavax, the vaccine manufactured by Merck & Co. to prevent shingles, has been approved by the U.S. Food and Drug Administration for adults ages 50 to 59 years old.
The National Vaccine Program Office has developed a new vaccine plan that outlines goals for improving the nation’s vaccine system.
Engineers at MIT have designed anew type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.
The California Assembly Health Committee passed legislation to protect Californians with life-threatening diseases from escalating insurance costs for medication.
Treatment with a higher dose of subcutaneous immunoglobulin (SCIG) correlates with reduced risk of infection and fewer missed school or work days in patients with primary humoral immunodeficiency (PI), according to findings from separate U.S. andEuropean trials of CSL Behring’s Hizentra 20% SCIG product.
A new monograph from The Joint Commission is intended to help healthcare organizations implement or enhance Tdap vaccination programs.
Panacea Biotec, an India-based biotechnology firm, has introduced a generic breast cancer treatment medicine called PacliALL.
The Centers for Medicare and Medicaid Services began charging a new application fee to all institutional providers.
SL Behring has developed a pharmacokinetic model that shows how the body absorbs, distributes, metabolizes and eliminates immunoglobulin following subcutaneous administration.
The U.S. Food and Drug Administration has granted marketing approval for Corifact Factor XIII Concentrate (Human) for the routine prophylactic treatment of congenital factor XIII(FXIII) deficiency.
The U.S.Food and Drug Administration has approved a novel type of cancer vaccine called Yervoy.
A report released by the KaiserFamily Foundation says that raising Medicare’s eligibility age by two years would save the federal government $7.6 billion, but those costs and more would shift to others.